Recent Updates
Recently added Catalysts

DPX-Survivac

Phase 2

Adult Diffuse Large Cell Lymphoma | Monoclonal antibody | Oncology |Merck & Company, Inc.|Last Updated: Sep 25, 2026

Development status

Highest phase Phase 2
Registered trials 3 across 2 sponsors since Nov 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment25

FDA Designations

No designations recorded

Clinical trial landscape

DPX-Survivac · 1 trial · 3 indications

Phase 2 1
NCT03349450DPX-Survivac and Checkpoint Inhibitor in DLBCLAdult Diffuse Large Cell Lymphoma
COMPLETED25 Analytics
PHASE2COMPLETED
DPX-Survivac and Checkpoint Inhibitor in DLBCL
Adult Diffuse Large Cell Lymphoma
NCT0334945025
Unlock trial analytics

Study Endpoints

Primary Endpoints

Objective Response Rate Using Modified Cheson Criteria to Treatment With DPX-Survivac and Low Dose Cyclophosphamide Administered Together With Pembrolizumab in Participants With Recurrent, Survivin-expressing B Cell Lymphomas
1 Year

Objective Response Rate is the combined Complete Response (CR) and Partial Response (PR) rates using Cheson Criteria (2007) for evaluation. Site Qualified Investigators use radiological reports to calculate the decrease in tumour size from baseline at protocol specified time points.

Secondary Endpoints

Duration of Response Using Modified Cheson Criteria.
2 Years
Time to Next Treatment
42 months
Evidence of Regression Using Waterfall Analyses
1 year
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Single Arm-InvestigationalEXPERIMENTALDPX-Survivac Priming dose of 0.5ml. DPX-Survivac Booster dose of 0.1ml. Pembrolizumab 200mg Intravenously. Cyclophosphamide 50mg Twice daily orally.

Interventions

NameTypeDescription
DPX-SurvivacBIOLOGICALDPX-Survivac Priming dose of 0.5ml on Study days 7 and 28. DPX-Survivac Booster dose of 0.1ml on Study days 84, 140, 196, 252, 308, and 364.
PembrolizumabBIOLOGICALPembrolizumab 200mg administered intravenously every 3 weeks, commencing on study day 7 to a total of 18 infusions
Cyclophosphamide 50mgDRUGCyclophosphamide 50mg twice daily by mouth, administered 7 days on / 7 days off, stating at study day 0, until study day 384
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria In order to be eligible for participation in this trial, the subject must: 1. Be willing and able to provide written informed consent/assent for the trial. 2. Male or female 18+ years of age on day of signing informed consent and of any racial or ethnic group 3. Has: A. hist...

Countries:Canada
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Merck & Company, Inc. (MRK)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with DCompanies A to ZEvery biotech and pharma company we track